In Alzheimer's disease (AD), amyloid β-protein (Aβ) production by regulated intramembrane proteolysis is crucial for pathogenicity. An unusual intramembrane cleavage generates various Aβ ...

Even if amyloid beta protein production is reduced, the presence of these stuck protein processing complexes could still ...

The technology – called Antibody Transport Vehicle (ATV): Amyloid beta – can be used to help amyloid-targeting drugs cross the blood brain barrier (BBB) more effectively, say the partners.

Although there are many outstanding questions about Alzheimer’s and a significant lack of effective drugs, scientists believe a protein called amyloid-beta plays an important role in the condition.

It also led to increased production of amyloid beta (Aβ), a protein that forms plaques in the brain and is associated with Alzheimer's. "Infectious agents have been implicated in the development ...

An experimental drug that clears amyloid beta from the brain cut the risk of developing Alzheimer’s by 50% among a group of 22 people with genetic mutations that all but guarantee they would ...

Researchers from National Taiwan University and collaborators have developed a novel way to observe and monitor carbon ...

(NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today ...

Although there are many outstanding questions about Alzheimer’s and a significant lack of effective drugs, scientists believe a protein called amyloid-beta plays an important role in the condition.

Donanemab is a monoclonal antibody against amyloid beta, intended to slow the progression of AD in adults with mild cognitive impairment or mild dementia by reducing amyloid plaques in the brain.

These findings suggested that neurovascular dysfunction may lead to reduced oxygen delivery to the brain, which could affect adenosine triphosphate production, and reduce beta-amyloid clearance.